By Gina Shaw
Cannabidiol (Epidiolex), an investigational cannabinoid-based therapy for epilepsy, significantly reduced seizures in children with Dravet syndrome, a rare and severe childhood-onset epilepsy for which there is currently no treatment, according to top-line data released March 14 by the drug’s manufacturer, GW Pharmaceuticals.
The Phase III study randomized 120 patients into two arms, receiving cannabidiol 20 mg/kg per day (n=61) or placebo (n=59) in combination with